Compare Gilead Sciences, Inc. (GILD) vs Rambus Inc. Common Stock (RMBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Rambus Inc. Common Stock — how do they compare? Gilead Sciences, Inc. trades at $155.08 (market cap $183.41B), while Rambus Inc. Common Stock trades at $89.17 (market cap $10.66B). The key difference: Gilead Sciences, Inc. is far larger — about 17.2× Rambus Inc. Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.22% dividend while Rambus Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Rambus Inc. Common Stock for 0 Days on average.
| GILD | RMBS | |
|---|---|---|
Market Cap | $183.41B | $10.66B |
Volume | 5,557,651 | 2,136,075 |
Sector | Health | Technology |
52-Week High | $155.80 | $170.66 |
52-Week Low | $117.85 | $79.73 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $206.48B | $9.85B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $153.54, up 2.07% today, near its consensus price target of $153.13. The stock shows a bullish technical trend with strong moving average signals. Recent earnings beat expectations in Q2 2026, though the company posted a net loss. Revenue growth is steady, with 2025 revenue at $29.44B, but profitability metrics like ROE and net income margin are negative. Positive news includes expanded HIV drug access in Latin America.
The outlook is mixed: analyst consensus is bullish with 65.52% buy ratings, but high debt and negative margins pose risks. Key catalysts include oncology pipeline advances and HIV franchise growth, while execution risks and competitive pressures remain concerns for investors.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →
